Metastatic breast cancer trials in Portugal

In Portugal 17 Also abroad 610

17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Where
Lisbon, Loures, Senhora Da Hora, Vila Nova de Gaia
Age
18 years and over
People
540 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00
Phase 2/3Taking people
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Where
Amadora-Lisbon, Lisbon, Loures, Matosinhos Municipality, Porto, Vila Nova de Gaia
Age
18 years and over
People
650 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00
Phase 3Taking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Coimbra, Lisbon, Porto, Senhora Da Hora, Vila Real
Age
18 years and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Lisbon, Porto
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1Not yet taking people in Portugal
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Porto
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Lisbon, Porto
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
Phase 3Taking people
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Where
Coimbra, Lisbon, Porto
Age
18 years and over
People
1,180 worldwide
Run by
Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01
Phase 2Taking people
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Where
Lisbon, Porto
Age
18 years and over
People
225 worldwide
Run by
Puma Biotechnology, Inc.
See details and how to joinNCT06369285 · EU 2024-511497-79-00
Phase 3Taking people
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Where
Coimbra, Lisbon, Porto, Senhora Da Hora, Vila Real
Age
18 years and over
People
1,000 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00
Phase 1Taking people
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Where
Porto
Age
18 years and over
People
62 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00
No phaseTaking people
EORTC Metastatic Breast Cancer Module Development
Where
Lisbon
Age
18 years and over
People
568 worldwide
Run by
University of Leeds
See details and how to joinNCT07806266
Phase 3Taking people
A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)
Where
Lisbon
Age
18 years and over
People
250 worldwide
Run by
WSG Women's Cancer Study Group GmbH
See details and how to join2024-511392-15-00 · EU 2024-511392-15-00
No phaseTaking people
DESTINY Breast Respond HER2-(Ultra)Low Europe
Where
Alcabideche, Lisboa, Amadora, Lisboa, Braga, Lisbon, Loures, Porto, Vila Real
Age
18 years and over
People
2,295 worldwide
Run by
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732
No phaseTaking people
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Where
Lisbon
Age
18 years and over
People
1,000 worldwide
Run by
Jules Bordet Institute
See details and how to joinNCT02102165
Phase 3Taking people
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Where
Lisbon
Age
18 years and over
People
250 worldwide
Run by
Women's Cancer Study Group GmbH
See details and how to joinNCT07281833
Phase 2Taking people
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Where
Alcabideche, Amadora, Aveiro, Guimaraes, Lisbon, Loures, Porto, Vila Real
Age
18 years and over
People
200 worldwide
Run by
MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00
Phase 3Taking people
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Where
Braga, Lisbon, Porto
Age
18 years and over
People
250 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT05950945 · EU 2023-505616-38-00